Tissue | Expression Dynamics | Abbreviation |
Colorectum (GSE201348) | | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
GC | | CAG: Chronic atrophic gastritis |
CAG with IM: Chronic atrophic gastritis with intestinal metaplasia |
CSG: Chronic superficial gastritis |
GC: Gastric cancer |
SIM: Severe intestinal metaplasia |
WIM: Wild intestinal metaplasia |
Liver | | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Oral Cavity | | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Thyroid | | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:19909281 | Liver | HCC | response to amino acid starvation | 33/7958 | 49/18723 | 3.86e-04 | 2.62e-03 | 33 |
GO:00718975 | Liver | HCC | DNA biosynthetic process | 99/7958 | 180/18723 | 4.66e-04 | 3.08e-03 | 99 |
GO:190435812 | Liver | HCC | positive regulation of telomere maintenance via telomere lengthening | 26/7958 | 37/18723 | 5.88e-04 | 3.74e-03 | 26 |
GO:000189011 | Liver | HCC | placenta development | 81/7958 | 144/18723 | 5.91e-04 | 3.75e-03 | 81 |
GO:00705551 | Liver | HCC | response to interleukin-1 | 80/7958 | 143/18723 | 7.95e-04 | 4.77e-03 | 80 |
GO:00510902 | Liver | HCC | regulation of DNA-binding transcription factor activity | 220/7958 | 440/18723 | 8.04e-04 | 4.82e-03 | 220 |
GO:003221211 | Liver | HCC | positive regulation of telomere maintenance via telomerase | 24/7958 | 34/18723 | 8.62e-04 | 5.13e-03 | 24 |
GO:007030222 | Liver | HCC | regulation of stress-activated protein kinase signaling cascade | 105/7958 | 195/18723 | 8.79e-04 | 5.20e-03 | 105 |
GO:200057312 | Liver | HCC | positive regulation of DNA biosynthetic process | 41/7958 | 66/18723 | 1.02e-03 | 5.86e-03 | 41 |
GO:003461211 | Liver | HCC | response to tumor necrosis factor | 132/7958 | 253/18723 | 1.14e-03 | 6.48e-03 | 132 |
GO:003249611 | Liver | HCC | response to lipopolysaccharide | 174/7958 | 343/18723 | 1.19e-03 | 6.62e-03 | 174 |
GO:007124112 | Liver | HCC | cellular response to inorganic substance | 119/7958 | 226/18723 | 1.26e-03 | 6.92e-03 | 119 |
GO:00712166 | Liver | HCC | cellular response to biotic stimulus | 128/7958 | 246/18723 | 1.53e-03 | 8.10e-03 | 128 |
GO:00341981 | Liver | HCC | cellular response to amino acid starvation | 30/7958 | 46/18723 | 1.56e-03 | 8.23e-03 | 30 |
GO:00712601 | Liver | HCC | cellular response to mechanical stimulus | 48/7958 | 81/18723 | 1.72e-03 | 8.96e-03 | 48 |
GO:003287222 | Liver | HCC | regulation of stress-activated MAPK cascade | 102/7958 | 192/18723 | 1.86e-03 | 9.49e-03 | 102 |
GO:00712226 | Liver | HCC | cellular response to lipopolysaccharide | 110/7958 | 209/18723 | 1.92e-03 | 9.77e-03 | 110 |
GO:00322001 | Liver | HCC | telomere organization | 86/7958 | 159/18723 | 2.06e-03 | 1.04e-02 | 86 |
GO:00096124 | Liver | HCC | response to mechanical stimulus | 113/7958 | 216/18723 | 2.20e-03 | 1.10e-02 | 113 |
GO:000223711 | Liver | HCC | response to molecule of bacterial origin | 181/7958 | 363/18723 | 2.58e-03 | 1.24e-02 | 181 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa05208 | Colorectum | AD | Chemical carcinogenesis - reactive oxygen species | 126/2092 | 223/8465 | 1.01e-24 | 1.68e-22 | 1.07e-22 | 126 |
hsa05010 | Colorectum | AD | Alzheimer disease | 174/2092 | 384/8465 | 1.82e-19 | 9.26e-18 | 5.91e-18 | 174 |
hsa05020 | Colorectum | AD | Prion disease | 133/2092 | 273/8465 | 2.47e-18 | 8.29e-17 | 5.29e-17 | 133 |
hsa05022 | Colorectum | AD | Pathways of neurodegeneration - multiple diseases | 201/2092 | 476/8465 | 4.54e-18 | 1.27e-16 | 8.09e-17 | 201 |
hsa05171 | Colorectum | AD | Coronavirus disease - COVID-19 | 113/2092 | 232/8465 | 9.90e-16 | 2.55e-14 | 1.63e-14 | 113 |
hsa05131 | Colorectum | AD | Shigellosis | 109/2092 | 247/8465 | 1.09e-11 | 2.44e-10 | 1.55e-10 | 109 |
hsa04520 | Colorectum | AD | Adherens junction | 50/2092 | 93/8465 | 1.52e-09 | 2.83e-08 | 1.81e-08 | 50 |
hsa05132 | Colorectum | AD | Salmonella infection | 102/2092 | 249/8465 | 7.65e-09 | 1.28e-07 | 8.17e-08 | 102 |
hsa04666 | Colorectum | AD | Fc gamma R-mediated phagocytosis | 46/2092 | 97/8465 | 9.10e-07 | 1.22e-05 | 7.77e-06 | 46 |
hsa05130 | Colorectum | AD | Pathogenic Escherichia coli infection | 79/2092 | 197/8465 | 1.05e-06 | 1.36e-05 | 8.65e-06 | 79 |
hsa05135 | Colorectum | AD | Yersinia infection | 58/2092 | 137/8465 | 3.90e-06 | 4.35e-05 | 2.78e-05 | 58 |
hsa04066 | Colorectum | AD | HIF-1 signaling pathway | 48/2092 | 109/8465 | 7.25e-06 | 7.84e-05 | 5.00e-05 | 48 |
hsa04919 | Colorectum | AD | Thyroid hormone signaling pathway | 51/2092 | 121/8465 | 1.71e-05 | 1.73e-04 | 1.10e-04 | 51 |
hsa04722 | Colorectum | AD | Neurotrophin signaling pathway | 50/2092 | 119/8465 | 2.28e-05 | 2.24e-04 | 1.43e-04 | 50 |
hsa05213 | Colorectum | AD | Endometrial cancer | 29/2092 | 58/8465 | 2.69e-05 | 2.57e-04 | 1.64e-04 | 29 |
hsa04723 | Colorectum | AD | Retrograde endocannabinoid signaling | 59/2092 | 148/8465 | 2.94e-05 | 2.73e-04 | 1.74e-04 | 59 |
hsa05216 | Colorectum | AD | Thyroid cancer | 21/2092 | 37/8465 | 3.05e-05 | 2.76e-04 | 1.76e-04 | 21 |
hsa05230 | Colorectum | AD | Central carbon metabolism in cancer | 33/2092 | 70/8465 | 3.61e-05 | 3.19e-04 | 2.03e-04 | 33 |
hsa05210 | Colorectum | AD | Colorectal cancer | 35/2092 | 86/8465 | 7.54e-04 | 5.49e-03 | 3.50e-03 | 35 |
hsa05417 | Colorectum | AD | Lipid and atherosclerosis | 73/2092 | 215/8465 | 1.31e-03 | 8.27e-03 | 5.27e-03 | 73 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
MAPK3 | SNV | Missense_Mutation | | c.454C>T | p.Arg152Trp | p.R152W | P27361 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-BH-A0E1-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
MAPK3 | insertion | Frame_Shift_Ins | novel | c.908_909insACTTTGGGAGGCCGAGGTGGGTG | p.Asp305TrpfsTer15 | p.D305Wfs*15 | P27361 | protein_coding | | | TCGA-A8-A07W-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | exemestane | SD |
MAPK3 | insertion | Frame_Shift_Ins | novel | c.1074_1075insGCTGTGGTGGGAGGACTGCTTGAACCTGGGAGAG | p.Arg359AlafsTer85 | p.R359Afs*85 | P27361 | protein_coding | | | TCGA-AN-A04A-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
MAPK3 | insertion | Frame_Shift_Ins | novel | c.504_505insGAGGGGCTGCCCACTCCTGAAAGGAACGGAC | p.Pro169GlufsTer23 | p.P169Efs*23 | P27361 | protein_coding | | | TCGA-BH-A0HQ-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Hormone Therapy | arimidex | SD |
MAPK3 | SNV | Missense_Mutation | rs774690695 | c.311G>A | p.Arg104Gln | p.R104Q | P27361 | protein_coding | tolerated(0.33) | benign(0.014) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
MAPK3 | SNV | Missense_Mutation | novel | c.819N>G | p.Ile273Met | p.I273M | P27361 | protein_coding | tolerated(0.11) | possibly_damaging(0.815) | TCGA-JW-A5VL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
MAPK3 | SNV | Missense_Mutation | | c.869N>C | p.Val290Ala | p.V290A | P27361 | protein_coding | tolerated(0.24) | benign(0.075) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR |
MAPK3 | SNV | Missense_Mutation | | c.173N>T | p.Ser58Leu | p.S58L | P27361 | protein_coding | deleterious(0.01) | possibly_damaging(0.78) | TCGA-AA-A01R-01 | Colorectum | colon adenocarcinoma | Male | <65 | III/IV | Chemotherapy | 5-fluorouracil | PD |
MAPK3 | SNV | Missense_Mutation | | c.251G>A | p.Arg84His | p.R84H | P27361 | protein_coding | deleterious(0.03) | probably_damaging(0.963) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
MAPK3 | SNV | Missense_Mutation | rs764219989 | c.631N>T | p.Arg211Trp | p.R211W | P27361 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-DM-A1HB-01 | Colorectum | colon adenocarcinoma | Male | >=65 | III/IV | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5595 | MAPK3 | TRANSCRIPTION FACTOR, KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | | (+)-ISOBICYCLOGERMACRENAL | CHEMBL2333548 | |
5595 | MAPK3 | TRANSCRIPTION FACTOR, KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | | ETOPOSIDE | ETOPOSIDE | 23999041 |
5595 | MAPK3 | TRANSCRIPTION FACTOR, KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | | BENZOTHIAZOL-2-YLAMINE | CHEMBL329785 | 22982122 |
5595 | MAPK3 | TRANSCRIPTION FACTOR, KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | | YUANHUADINE | YUANHUADINE | 21916433 |
5595 | MAPK3 | TRANSCRIPTION FACTOR, KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | | CIMIRACEMATE A | CIMIRACEMATE A | 19835377 |
5595 | MAPK3 | TRANSCRIPTION FACTOR, KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | | SELENIUM | | 14744887 |
5595 | MAPK3 | TRANSCRIPTION FACTOR, KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | | NSC-753574 | CHEMBL2088730 | 22982122 |
5595 | MAPK3 | TRANSCRIPTION FACTOR, KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | | PD-153035 | CHEMBL29197 | 17681471 |
5595 | MAPK3 | TRANSCRIPTION FACTOR, KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | | MADOLIN A | MADOLIN A | |
5595 | MAPK3 | TRANSCRIPTION FACTOR, KINASE, DRUGGABLE GENOME, SERINE THREONINE KINASE, ENZYME | | VOLVALERENAL D | VOLVALERENAL D | |